These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
9. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Rezaie AR Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of low-molecular-weight heparin reversal by platelet factor 4. Fiore MM; Mackie IM Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682 [TBL] [Abstract][Full Text] [Related]
11. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
12. Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns. Sissi C; Naggi A; Torri G; Palumbo M Semin Thromb Hemost; 2003 Dec; 29(6):661-70. PubMed ID: 14719183 [TBL] [Abstract][Full Text] [Related]
13. New antithrombin-based anticoagulants. Desai UR Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167 [TBL] [Abstract][Full Text] [Related]
16. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667 [TBL] [Abstract][Full Text] [Related]
17. The importance of anti-factor Xa and antithrombin activities of low molecular weight heparins. Lane DA; Ryan K J Lab Clin Med; 1990 Aug; 116(2):269-70. PubMed ID: 2394942 [No Abstract] [Full Text] [Related]
18. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. Alban S Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163 [TBL] [Abstract][Full Text] [Related]
19. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Petitou M; van Boeckel CA Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558 [TBL] [Abstract][Full Text] [Related]
20. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. Nader HB; Pinhal MA; Baú EC; Castro RA; Medeiros GF; Chavante SF; Leite EL; Trindade ES; Shinjo SK; Rocha HA; Tersariol IL; Mendes A; Dietrich CP Braz J Med Biol Res; 2001 Jun; 34(6):699-709. PubMed ID: 11378657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]